Prospecto: Information for the user
Levetiracetam Kern Pharma 1000 mg film-coated tablets EFG
Levetiracetam
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
−Keep this prospect, as you may need to read it again.
−If you have any doubts, consult your doctor or pharmacist.
−This medicine has been prescribed for you, and you should not give it to other people even if they have the same symptoms as you, as it may harm them.
−If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.
1.What is Levetiracetam Kern Pharma andwhat it is used for
2.What you need to know before starting to take Levetiracetam Kern Pharma
3.How to take Levetiracetam Kern Pharma
4.Possible adverse effects
5.Storage of Levetiracetam Kern Pharma
6.Contents of the package and additional information
Levetiracetam Kern Pharma is an antiepileptic medication (a medication for the treatment of seizures in epilepsy).
Levetiracetam Kern Pharma is used:
Do not take Levetiracetam Kern Pharma
Warnings and precautions
Inform your doctor or pharmacist if any of the following adverse effects worsen or last more than a few days:
normal or if you or your family and friends notice significant changes in mood or behavior.
Taking other medications
Inform your doctor or pharmacistif you are using or have recently used other medications, including those purchased without a prescription.
Taking Levetiracetam Kern Pharma with food and beverages
You can take Levetiracetam Kern Pharma with or without meals. As a precaution, do not take Levetiracetam Kern Pharma with alcohol.
Pregnancy and breastfeeding
Consult your doctor or pharmacist before using any medication.
If you are pregnant or think you may be pregnant, inform your doctor.
Levetiracetam Kern Pharma should not be used during pregnancy unless strictly necessary. The risk to the baby during pregnancy is unknown. In animal studies, levetiracetam has shown unwanted effects on reproduction at doses higher than those you may need to control your seizures.
Breastfeeding is not recommended during treatment.
Driving and operating machinery
Levetiracetam may impair your ability to drive or operate tools or machinery, as it may cause drowsiness. This is more likely at the beginning of treatment or when the dose is increased. Do not drive or use machinery until it is confirmed that your ability to perform these activities is not affected.
Follow exactly the administration instructions of Levetiracetam Kern Pharma as indicated by your doctor. Consult your doctor if you have any doubts.
Levetiracetam should be taken twice a day, once in the morning and once at night, approximately at the same time each day.
Take the number of tablets prescribed by your doctor.
Monotherapy
Dosage in adults and adolescents (16 years of age and older):
Dosage: between 1,000 mg and 3,000 mg per day.
When starting to take levetiracetam, your doctor will prescribe alower dosefor two weeks before administering the general lowest dosage.
For example: for a daily dose of 2,000 mg, you should take 1 tablet in the morning and 1 tablet at night.
Concomitant therapy
Dosage in adults and adolescents (12 to 17 years) with a weight of 50 kg or more:
Dosage: between 1,000 mg and 3,000 mg per day.
For example: for a daily dose of 2,000 mg, you should take 1 tablet in the morning and 1 tablet at night.
Dosage in infants (6 to 23 months), children (2 to 11 years), and adolescents (12 to 17 years) with a weight less than 50 kg:
Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to age, weight, and dosage.
Levetiracetam 100 mg/ml oral solution is a more suitable presentation for infants and children under 6 years.
Dosage: between 20 mg per kg of body weight and 60 mg per kg of body weight per day.
Dosage in infants (1 month to less than 6 months):
Levetiracetam 100 mg/ml oral solution is a more suitable presentation for infants under 6 months.
Administration form:
Swallow the Levetiracetam Kern Pharma tablets with a sufficient amount of liquid (e.g., a glass of water).
Treatment duration:
If you take more Levetiracetam Kern Pharma than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
The possible adverse effects of a levetiracetam overdose are drowsiness, agitation, aggression, decreased alertness, respiratory inhibition, and coma.
Contact your doctor if you have taken more tablets than you should. Your doctor will establish the best possible treatment for the overdose.
If you forgot to take Levetiracetam Kern Pharma
Contact your doctor if you have missed one or more doses.
Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Levetiracetam Kern Pharma
Like with other antiepileptic medications, the discontinuation of levetiracetam treatment should be done gradually to avoid an increase in seizures.
If you have any other doubts about the use of this product, ask your doctor or pharmacist.
Like all medicines, Levetiracetam Kern Pharma may cause side effects, although not everyone will experience them.
Inform your doctor if you have any of the following side effects and they concern you.
Some side effects such as drowsiness, weakness, and dizziness may be more frequent when starting treatment or increasing the dose. However, these side effects should decrease over time.
Inform your doctor immediately, or go to the emergency service of your nearest hospital if you experience:
- weakness, dizziness, or difficulty breathing, as these may be signs of a severe allergic reaction (anaphylactic)
The frequency of the possible side effects listed below is defined as follows:
very common (may affect more than 1 in 10 patients)
common (may affect between 1 and 10 in 100 patients)
uncommon (may affect between 1 and 10 in 1,000 patients)
rare (may affect between 1 and 10 in 10,000 patients)
very rare (may affect fewer than 1 in 10,000 patients)
frequency not known (cannot be estimated from available data)
Very common:
Common:
Rare:
The prevalence is significantly higher in Japanese patients compared to non-Japanese patients.
Frequency not known:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of reach and sight of children.
Do not use this medicine after the expiration date that appears on the carton and in the blister after CAD.
The expiration date is the last day of the month indicated.
This medicine does not require special conditions for conservation.
Medicines should not be thrown into the drains or trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy.If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need.By doing so, you will help protect the environment.
Composition of Levetiracetam Kern Pharma 1,000 mg film-coated tablets
-The active ingredient is Levetiracetam. Each film-coated tablet contains 1,000 mg of Levetiracetam.
-The other components are:
Tablet core: croscarmellose sodium, anhydrous colloidal silica, magnesium stearate.
Film coating: Opadry 85F18422 (partially hydrolyzed polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc).
Appearance of the product and content of the packaging
The film-coated tablets are white, oval-shaped, and scored on one side. The score serves to break and facilitate swallowing but not to divide into equal doses.
The packaging contains 30 or 60 film-coated tablets.
Levetiracetam Kern Pharma is also available in film-coated tablets of 250 mg in packaging of 60 tablets and of 500 mg in packaging of 60 and 100 tablets..
Only some packaging sizes may be commercially available.
Marketing authorization holder
Kern Pharma, S.L.
Venus, 72 - Pol. Ind.Colón II
08228 Terrassa - Barcelona
Spain
Responsible for manufacturing
NOUCOR HEALTH, S.A.
Av. Camí Reial, 51-57
08184-Palau-solità i Plegamans
(Barcelona-Spain)
Last review date of this leaflet: October 2019
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.